Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)

Summary

The use of hydroxyurea in sickle cell disease patients with glomerular hyperfiltration and renal failure requires a specific monitoring and dose adjustment in order to remain within the therapeutic interval while limiting the risk of toxicity or therapeutic failure. For this reason the investigators propose to compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure.

Timeline

Start

2015-09-03

Primary completion

2016-11

Completion

2016-11-28

Drugs

Indications